BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1287 related articles for article (PubMed ID: 24487277)

  • 1. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing.
    Gerlinger M; Horswell S; Larkin J; Rowan AJ; Salm MP; Varela I; Fisher R; McGranahan N; Matthews N; Santos CR; Martinez P; Phillimore B; Begum S; Rabinowitz A; Spencer-Dene B; Gulati S; Bates PA; Stamp G; Pickering L; Gore M; Nicol DL; Hazell S; Futreal PA; Stewart A; Swanton C
    Nat Genet; 2014 Mar; 46(3):225-233. PubMed ID: 24487277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular genetics of clear-cell renal cell carcinoma.
    Brugarolas J
    J Clin Oncol; 2014 Jun; 32(18):1968-76. PubMed ID: 24821879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.
    Liao L; Testa JR; Yang H
    Cancer Genet; 2015 May; 208(5):206-14. PubMed ID: 25873528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
    Brugarolas J
    Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomics and clinical correlates of renal cell carcinoma.
    Mitchell TJ; Rossi SH; Klatte T; Stewart GD
    World J Urol; 2018 Dec; 36(12):1899-1911. PubMed ID: 30099580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
    Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
    Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.
    Braun DA; Hou Y; Bakouny Z; Ficial M; Sant' Angelo M; Forman J; Ross-Macdonald P; Berger AC; Jegede OA; Elagina L; Steinharter J; Sun M; Wind-Rotolo M; Pignon JC; Cherniack AD; Lichtenstein L; Neuberg D; Catalano P; Freeman GJ; Sharpe AH; McDermott DF; Van Allen EM; Signoretti S; Wu CJ; Shukla SA; Choueiri TK
    Nat Med; 2020 Jun; 26(6):909-918. PubMed ID: 32472114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development.
    Duns G; Hofstra RM; Sietzema JG; Hollema H; van Duivenbode I; Kuik A; Giezen C; Jan O; Bergsma JJ; Bijnen H; van der Vlies P; van den Berg E; Kok K
    Hum Mutat; 2012 Jul; 33(7):1059-62. PubMed ID: 22461374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
    Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
    Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.
    Gossage L; Murtaza M; Slatter AF; Lichtenstein CP; Warren A; Haynes B; Marass F; Roberts I; Shanahan SJ; Claas A; Dunham A; May AP; Rosenfeld N; Forshew T; Eisen T
    Genes Chromosomes Cancer; 2014 Jan; 53(1):38-51. PubMed ID: 24166983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling.
    Pal SK; Choueiri TK; Wang K; Khaira D; Karam JA; Van Allen E; Palma NA; Stein MN; Johnson A; Squillace R; Elvin JA; Chmielecki J; Yelensky R; Yakirevich E; Lipson D; Lin DI; Miller VA; Stephens PJ; Ali SM; Ross JS
    Eur Urol; 2016 Sep; 70(3):516-21. PubMed ID: 26149668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations.
    Karlo CA; Di Paolo PL; Chaim J; Hakimi AA; Ostrovnaya I; Russo P; Hricak H; Motzer R; Hsieh JJ; Akin O
    Radiology; 2014 Feb; 270(2):464-71. PubMed ID: 24029645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis.
    Wang SS; Gu YF; Wolff N; Stefanius K; Christie A; Dey A; Hammer RE; Xie XJ; Rakheja D; Pedrosa I; Carroll T; McKay RM; Kapur P; Brugarolas J
    Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16538-43. PubMed ID: 25359211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.
    Bi M; Zhao S; Said JW; Merino MJ; Adeniran AJ; Xie Z; Nawaf CB; Choi J; Belldegrun AS; Pantuck AJ; Kluger HM; Bilgüvar K; Lifton RP; Shuch B
    Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2170-5. PubMed ID: 26864202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative radiogenomics analysis for predicting molecular features and survival in clear cell renal cell carcinoma.
    Zeng H; Chen L; Wang M; Luo Y; Huang Y; Ma X
    Aging (Albany NY); 2021 Mar; 13(7):9960-9975. PubMed ID: 33795526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma.
    Piva F; Giulietti M; Occhipinti G; Santoni M; Massari F; Sotte V; Iacovelli R; Burattini L; Santini D; Montironi R; Cascinu S; Principato G
    Oncotarget; 2015 Oct; 6(31):32161-8. PubMed ID: 26452128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific genomic aberrations predict survival, but low mutation rate in cancer hot spots, in clear cell renal cell carcinoma.
    Köhn L; Svenson U; Ljungberg B; Roos G
    Appl Immunohistochem Mol Morphol; 2015; 23(5):334-42. PubMed ID: 24992170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
    Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
    Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.
    Nickerson ML; Jaeger E; Shi Y; Durocher JA; Mahurkar S; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Mukeria A; Holcatova I; Schmidt LS; Toro JR; Karami S; Hung R; Gerard GF; Linehan WM; Merino M; Zbar B; Boffetta P; Brennan P; Rothman N; Chow WH; Waldman FM; Moore LE
    Clin Cancer Res; 2008 Aug; 14(15):4726-34. PubMed ID: 18676741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Independent Tumor Origin in Two Cases of Synchronous Bilateral Clear Cell Renal Cell Carcinoma.
    Ji Z; Zhao J; Zhao T; Han Y; Zhang Y; Ye H
    Sci Rep; 2016 Jul; 6():29267. PubMed ID: 27383411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.